Treatment of familial erythromelalgia with venlafaxine [11]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 6, 2007, Pages 836-837

  Firmin, D ^a   Roguedas, A M ^a   Greco, M ^a   Morvan, C ^a   Legoupil, D ^a   Fleuret, C ^a   Misery, Laurent ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; VENLAFAXINE; VOLTAGE GATED SODIUM CHANNEL; WATER;

ADULT; AMINO ACID SUBSTITUTION; CACHEXIA; CASE REPORT; CHANNELOPATHY; DISEASE SEVERITY; DOMINANT INHERITANCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROMELALGIA; FAMILIAL DISEASE; FEMALE; HUMAN; INSOMNIA; LETTER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL GANGLION; STOMACH PAIN; SYMPTOMATOLOGY; ULCER; VERTIGO; WATER IMMERSION;

ADULT; CYCLOHEXANOLS; ERYTHROMELALGIA; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 34249056076     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.02039.x     Document Type: Letter

References (10)

1. Legroux-Crespel E, Sassolas B, Guillet G et al. Traitement de 1 érythermalgie familiale par l'association lidocaïne-mexilétine. Ann Dermatol Venereol 2003; 130: 429-433.
2. Stephen G, Sulayman D. Erythromelalgia: A hereditary pain syndrome enters the molecular era. Ann Neurol 2005; 57: 785-788.
3. Yang Y, Wang Y, Li S et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythromelalgia. J Med Genet 2004; 41: 171-74.
4. Dib-Hajj SD, Rush AM, Cummins TR et al. Gain-of-function mutation in Navl.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005; 128: 1847-1854.
5. Drenth JP, Finley WH, Breedveld GJ et al. The primary erythromelalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001; 68: 1277-1282.
6. Drenth J, Morsche R, Guillet G et al. SCN9A mutations define primary erythromelalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 2005; 124: 1333-1338.
7. Weil-Fugazza J. Role of the spinal serotoninergic, noradrenergic and doparninergic systems in the mechanism of analgesia. Cah Anesthesiol 1994; 42: 707-712.
8. Rudikoff D, Jaffe LA. Erythromelalgia: Response to serotonin reuptake inhibitors. J Am Acad Dermatol 1997; 37: 1-3.
9. Moiin A, Yashar SS, Sanchez JE, Yashbar B. Treatment of erythromelalgia with aserotonin/noradrenaline reuptake inhibitor. Br J Dermatol 2002; 146: 336-337.
10. Di Caudo DJ, Kelley LA. Alleviation of erythromelalgia with venlafaxine. Archdermatol 2004; 140: 621-623.